References
1.
Mayer
RJ
, Davis
RB
, Schiffer
CA
, Berg
DT
, Powell
BL
, Schulman
P
, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B
. N Engl J Med
. 1994
;331
:896
–903
. .2.
Byrd
JC
, Ruppert
AS
, Mrózek
K
, Carroll
AJ
, Edwards
CG
, Arthur
DC
, Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
. J Clin Oncol
. 2004
;22
:1087
–94
. .3.
Burnett
AK
, Russell
NH
, Hills
RK
, Knapper
S
, Freeman
S
, Huntly
B
, Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses
. J Clin Oncol
. 2021
;39
(8
):890
–901
. .4.
Miyawaki
S
, Sakamaki
H
, Ohtake
S
, Emi
N
, Yagasaki
F
, Mitani
K
, A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study
. Cancer
. 2005
;104
:2726
–34
. .5.
Dohner
H
, Estey
E
, Grimwade
D
, Amadori
S
, Appelbaum
FR
, Buchner
T
, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
. Blood
. 2017
;129
:424
–47
.6.
Estey
EH
. Acute myeloid leukemia: 2019 update on risk-stratification and management
. Am J Hematol
. 2018
;93
:1267
–91
. .7.
Ostgard
LSG
, Lund
JL
, Norgaard
JM
, Norgaard
M
, Medeiros
BC
, Nielsen
B
, Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study
. Biol Blood Marrow Transplant
. 2018
;24
:314
–23
.8.
Sung
L
, Aplenc
R
, Alonzo
TA
, Gerbing
RB
, Wang
YC
, Meshinchi
S
, Association between prolonged neutropenia and reduced relapse risk in pediatric AML: a report from the Children’s Oncology Group
. Int J Cancer
. 2016
;139
:1930
–5
. .9.
Aoki
T
, Takahashi
H
, Tanaka
S
, Shiba
N
, Hasegawa
D
, Iwamoto
S
, Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study
. Br J Haematol
. 2021
;193
(1
):176
–80
. .10.
Khalil
F
, Cualing
H
, Cogburn
J
, Miles
L
. The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study
. Arch Pathol Lab Med
. 2007
;131
:1281
–9
. .11.
Wilkins
BS
, Bostanci
AG
, Ryan
MF
, Jones
DB
. Haemopoietic regrowth after chemotherapy for acute leukaemia: an immunohistochemical study of bone marrow trephine biopsy specimens
. J Clin Pathol
. 1993
;46
:915
–21
. .12.
Pinto
A
, De Filippi
R
, Frigeri
F
, Corazzelli
G
, Normanno
N
. Aging and the hemopoietic system
. Crit Rev Oncol Hematol
. 2003
;48
:S3
–12
. .13.
Portugal
RD
, Garnica
M
, Nucci
M
. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve
. J Clin Oncol
. 2009
;27
:3849
–54
. .14.
Kimura
S
, Wada
H
, Ishihara
Y
, Kawamura
K
, Sakamoto
K
, Yamasaki
R
, D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine
. Hematology
. 2014
;19
:107
–12
. .15.
Kanda
Y
. Investigation of the freely available easy-to-use software “EZR” for medical statistics
. Bone Marrow Transplant
. 2013
;48
:452
–8
. .16.
Periclou
AP
, Avramis
VI
. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias
. Cancer Chemother Pharmacol
. 1996
;39
:42
–50
. .17.
Capizzi
RL
, Yang
JL
, Cheng
E
, Bjornsson
T
, Sahasrabudhe
D
, Tan
RS
, Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia
. J Clin Oncol
. 1983
;1
:763
–71
. .18.
Slevin
ML
, Piall
EM
, Aherne
GW
, Harvey
VJ
, Johnston
A
, Lister
TA
. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid
. J Clin Oncol
. 1983
;1
:546
–51
. .19.
Fleming
RA
, Capizzi
RL
, Rosner
GL
, Oliver
LK
, Smith
SJ
, Schiffer
CA
, Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study
. Cancer Chemother Pharmacol
. 1995
;36
:425
–30
. .20.
Hiddemann
W
, Schleyer
E
, Uhrmeister
C
, Aul
CH
, Maschmeyer
G
, Heinecke
A
, High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: preliminary clinical and pharmacological data of a randomized comparison
. Cancer Treat Rev
. 1990
;17
:279
–85
. .21.
Piscitelli
SC
, Rodvold
KA
, Rushing
DA
, Tewksbury
DA
. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer
. Clin Pharmacol Ther
. 1993
;53
:555
–61
. .22.
Estey
EH
, Shen
Y
, Thall
PF
. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB
. Blood
. 2000
;95
:72
–7
. .23.
Lohmann
DJA
, Asdahl
PH
, Abrahamsson
J
, Ha
SY
, Jonsson
OG
, Kaspers
GJL
, Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia
. Pediatr Blood Cancer
. 2018
;65
:e27231
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.